查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1421682

神经生物标记市场、份额、规模、趋势、行业分析报告：按类型、按应用、按最终用途、按地区、按细分市场、预测，2024-2032 年

Neurological Biomarkers Market Share, Size, Trends, Industry Analysis Report, By Type (Metabolomic, Genomic, Imaging, Proteomic, Others); By Application; By End-Use; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 115 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，到2032年，全球神经生物标记市场规模预计将达到248.3亿美元。 该报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

神经生物标记可作为测量和评估症状并确定对特定治疗的药理反应的指标。 广泛应用于自闭症、帕金森氏症、忧郁症等多种疾病的诊断。 这些生物标记分为几个类别，包括代谢组学、成像、基因组学和蛋白□□质组学。

神经生物标记（包括特征生物标记）的进步正在提高神经系统疾病治疗的有效性，加速药物开发，实现早期诊断并促进非侵入性检测。 此外，数位生物标记正在为製药公司提供有价值的补充资讯并帮助临床试验决策，从而推动神经生物标记市场的成长。

在个人化医疗领域，神经退化性疾病的神经生物标记研究进展迅速，大量分子正在被评估并与各种神经退化性疾病相关。 精准医疗的这种演变正在对生物製药行业产生重大影响，并为从生物製药公司到诊断公司、从商业运营到研发的各种参与者带来重大变化。

然而，较长的生物标记开发週期和较高的启动成本可能会阻碍市场成长。 从正面的方面来看，由于有机构在不同的研究阶段提供资金，因此市场扩张有充足的机会。 值得注意的是，美国国立卫生研究院 (NIH) 已拨款额外资金支持与阿兹海默症和大脑老化的健康差异相关的研究，进一步刺激市场成长。

此外，国家医学图书馆 2021 年 6 月发表的一项研究强调了冠状动脉疾病 (CAD) 对全球健康的重大影响。 光是 CAD 每年就导致约 61 万人死亡，占估计死亡人数的四分之一，是美国的第一大死因。 随着 CAD 发病率的增加，对有效的神经生物标记设备来满足这一紧迫的医疗需求的需求不断增长。 因此，预计该因素将在整个预测期内推动对神经生物标记的需求。

神经生物标记物市场报告亮点

  • 蛋白质体学领域将在2022年获得最高的收入份额蛋白质组学生物标记物发挥着举足轻重的作用，特别是当仅仅依靠mRNA表达无法揭示多种翻译后修饰的功能意义时。我会实现它。 在这种情况下，蛋白质组生物标记对于透过密切检测蛋白质特征和翻译后修饰的变化来准确诊断疾病的发病和进展至关重要。 这些生物标记在揭示阿兹海默症 (AD) 等复杂且无法解释的疾病背后的细胞变化方面显示出显着的功效。 AD 的重要蛋白质体生物标记包括胶质纤维酸性蛋白 (GFAP)、铜锌超氧化物歧化□ (SOD1)、AB42、tau 和 AB 胜□。 新产品的不断推出预计将推动市场成长。
  • 阿兹海默症在 2022 年占据了最大的市场份额，预计在预测期内将继续占据主导地位。 这一趋势主要是由于这种疾病的盛行率不断增加以及人们越来越重视早期诊断和及时治疗。
  • 到 2022 年，北美将成为最大市场。 北美神经生物标记市场占据重要份额，预计在即将到来的预测期内将呈现显着的复合年增长率。 这种增长是由多种因素推动的，包括神经系统疾病的高盛行率以及旨在支持该行业的政府举措的激增。 此外，市场有望受益于新产品的推出和对生物标记物需求的增加。 该地区积极资助研究和创新生物标记开发，进一步促进市场扩张。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第 4 章全球神经生物标记市场洞察

  • 神经生物标记物市场 - 应用快照
  • 神经生物标记物市场动态
    • 推动者和机会
      • 神经系统疾病的发生率增加
      • 增加对生物标记研发 (R&D) 的投资
    • 抑制因素和挑战
      • 初始投资成本高，生物标记开发週期长
  • PESTEL 分析
  • 神经生物标记物市场应用趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第五章全球神经生物标记市场，依类型

  • 主要发现
  • 简介
  • 代谢组学
  • 基因组
  • 成像
  • 蛋白质体学
  • 其他

第 6 章全球神经生物标记市场（依最终用途）

  • 主要发现
  • 简介
  • 独立临床诊断中心
  • 研究机构等
  • 医院和医院实验室

第 7 章全球神经生物标记市场（按应用）

  • 主要发现
  • 简介
  • 自闭症谱系障碍
  • 帕金森氏症
  • 阿兹海默症
  • 多发性硬化症
  • 其他

第 8 章全球神经生物标记市场（按地区）

  • 主要发现
  • 简介
    • 神经生物标记市场评估，地区，2019-2032
  • 神经生物标记市场 - 北美
    • 北美：神经生物标记物市场（按类型），2019-2032 年
    • 北美：神经生物标记市场，按应用划分，2019-2032 年
    • 北美：神经生物标记市场，依最终用途，2019-2032 年
    • 神经生物标记市场 - 美国
    • 神经生物标记市场 - 加拿大
  • 神经生物标记市场 - 欧洲
    • 欧洲：神经生物标记市场（按类型），2019-2032 年
    • 欧洲：神经生物标记物市场，按应用划分，2019-2032 年
    • 欧洲：神经生物标记市场，依最终用途分类，2019-2032 年
    • 神经生物标记市场 - 英国
    • 神经生物标记市场 - 法国
    • 神经生物标记市场 - 德国
    • 神经生物标记市场 - 义大利
    • 神经生物标记市场 - 西班牙
    • 神经生物标记市场 - 荷兰
    • 神经生物标记市场 - 俄罗斯
  • 神经生物标记市场 - 亚太地区
    • 亚太地区：神经生物标记市场（按类型），2019-2032 年
    • 亚太地区：神经生物标记市场，按应用划分，2019-2032 年
    • 亚太地区：神经生物标记市场，依最终用途，2019-2032 年
    • 神经生物标记市场 - 中国
    • 神经生物标记市场 - 印度
    • 神经生物标记市场 - 马来西亚
    • 神经生物标记物市场 - 日本
    • 神经生物标记市场 - 印度尼西亚
    • 神经生物标记物市场 - 韩国
  • 神经生物标记市场 - 中东和非洲
    • 中东和非洲：神经生物标记市场（按类型），2019-2032 年
    • 中东和非洲：神经生物标记市场，按应用划分，2019-2032 年
    • 中东和非洲：神经生物标记市场（以最终用途），2019-2032 年
    • 神经生物标记市场 - 沙乌地阿拉伯
    • 神经生物标记市场 - 阿拉伯联合大公国
    • 神经生物标记市场 - 以色列
    • 神经生物标记市场 - 南非
  • 神经生物标记市场 - 拉丁美洲
    • 拉丁美洲：神经生物标记市场（按类型），2019-2032 年
    • 拉丁美洲：神经生物标记市场，按应用划分，2019-2032 年
    • 拉丁美洲：神经生物标记市场，依最终用途划分，2019-2032 年
    • 神经生物标记市场 - 墨西哥
    • 神经生物标记市场 - 巴西
    • 神经生物标记市场 - 阿根廷

第九章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协议/揭露

第十章公司简介

  • Abbott
  • Alseres Pharmaceuticals, Inc.
  • BANYAN BIOMARKERS, INC.
  • Bio-Rad Laboratories, Inc.
  • DiaGenic ASA
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Quanterix
  • Thermo Fisher Scientific, Inc.
Product Code: PM4022

The global neurological biomarkers market size is expected to reach USD 24.83 billion by 2032, according to a new study by Polaris Market Research. The report "Neurological Biomarkers Market Share, Size, Trends, Industry Analysis Report, By Type (Metabolomic, Genomic, Imaging, Proteomic, Others); By Application; By End-Use; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Neurological biomarkers serve as indicators for measuring and assessing symptoms or determining a pharmacological response to a specific treatment. They find extensive application in the diagnosis of various conditions, including autism, Parkinson's disease, and depression. These biomarkers fall into several categories, including metabolomics, imaging, genomics, and proteomics.

Advancements in neurological biomarkers, encompassing signature biomarkers, are enhancing the effectiveness of treating neurological diseases, expediting drug development, enabling early diagnosis, and facilitating noninvasive testing. Furthermore, digital biomarkers are supplying valuable supplementary information to pharmaceutical companies, aiding in clinical trial decision-making and, consequently, propelling the growth of the neurological biomarkers market.

In the realm of personalized medicine, neurological biomarker research for neurodegenerative diseases represents a rapidly advancing field, with numerous molecules being associated and evaluated in the context of various neurodegenerative disorders. This evolution in precision medicine is significantly influencing the biopharmaceutical industry, leading to substantial transformations across various players, from biopharma to diagnostics companies, with roles ranging from commercial operations to research and development.

Even with this, the market's growth may be hindered by protracted biomarker development cycles and substantial startup costs. On a positive note, the presence of organizations offering funding at various research stages presents ample opportunities for market expansion. Notably, the National Institutes of Health (NIH) is allocating additional funds to support research related to health disparities in Alzheimer's and brain aging, further stimulating market growth.

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective Neurological Biomarkers devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for Neurological Biomarkers throughout the forecast period.

Neurological Biomarkers Market Report Highlights

  • In 2022, the Proteomic segment dominated with the highest revenue share. Proteomic biomarkers play a pivotal role, especially when relying solely on mRNA expression falls short in revealing the functional implications of diverse post-translational modifications. In such scenarios, proteomic biomarkers become indispensable for accurately diagnosing the onset and progression of diseases by meticulously detecting protein signatures and post-translational changes. These biomarkers have demonstrated remarkable effectiveness in unveiling the cellular alterations underlying complex and unexplained conditions like Alzheimer's disease (AD). Prominent proteomic biomarkers for AD include glial fibrillary acidic protein (GFAP), copper-zinc superoxide dismutase (SOD1), AB42, tau, and AB peptides. The continuous introduction of new products is expected to be a driving force behind market growth.
  • Alzheimer's disease secured the largest market share in 2022 and is expected to continue its dominance during the forecast period. This trend is mainly driven by the rising prevalence of the disease and a heightened focus on early diagnosis and prompt treatment.
  • In 2022, North America took the lead as the largest market. The neurological biomarkers market in North America holds a substantial share and is expected to exhibit a noteworthy CAGR in the upcoming forecast period. This growth is underpinned by several factors, including the high prevalence of neurological disorders and the surge in government initiatives aimed at supporting this sector. Moreover, the market is set to gain from a growing influx of new product launches and an increasing demand for biomarkers. The region maintains robust funding for research and the development of innovative biomarkers, further contributing to market advancement.
  • The global key market players include: Abbott, Alseres Pharmaceuticals, Inc., BANYAN BIOMARKERS, INC., Bio-Rad Laboratories, Inc., DiaGenic ASA, Johnson & Johnson Services, Inc., Merck & Co., Inc., Myriad Genetics, Inc., Quanterix, Thermo Fisher Scientific, Inc.

Polaris Market Research has segmented the Neurological Biomarkers market report based on type, application, end-use, and region:

Neurological Biomarkers, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Metabolomic
  • Genomic
  • Imaging
  • Proteomic
  • Others

Neurological Biomarkers, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Autism Spectrum Disorder
  • Parkinson's Disease
  • Alzheimer's Disease
  • Multiple Sclerosis
  • Others

Neurological Biomarkers, End-Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Independent clinical diagnostic centers
  • Research Organizations and Others
  • Hospital & Hospital Laboratories

Neurological Biomarkers, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Neurological Biomarkers Market Insights

  • 4.1. Neurological Biomarkers Market - Application Snapshot
  • 4.2. Neurological Biomarkers Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Incidence of Neurological Disorders
      • 4.2.1.2. Elevated investment in Research and Development (R&D) for biomarkers
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High initial investment expenses and lengthy biomarker development cycles
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Neurological Biomarkers Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Neurological Biomarkers Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Metabolomic
    • 5.3.1. Global Neurological Biomarkers Market, by Metabolomic, by Region, 2019-2032 (USD Billion)
  • 5.4. Genomic
    • 5.4.1. Global Neurological Biomarkers Market, by Genomic, by Region, 2019-2032 (USD Billion)
  • 5.5. Imaging
    • 5.5.1. Global Neurological Biomarkers Market, by Imaging, by Region, 2019-2032 (USD Billion)
  • 5.6. Proteomic
    • 5.6.1. Global Neurological Biomarkers Market, by Proteomic, by Region, 2019-2032 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Neurological Biomarkers Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Neurological Biomarkers Market, by End Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 6.3.Independent clinical diagnostic centers
    • 6.3.1. Global Neurological Biomarkers Market, by Independent clinical diagnostic centers, by Region, 2019-2032 (USD Billion)
  • 6.4. Research Organizations and Others
    • 6.4.1. Global Neurological Biomarkers Market, by Research Organizations and Others, by Region, 2019-2032 (USD Billion)
  • 6.5. Hospital & Hospital Laboratories
    • 6.5.1. Global Neurological Biomarkers Market, by Hospital & Hospital Laboratories, by Region, 2019-2032 (USD Billion)

7. Global Neurological Biomarkers Market, by Application

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 7.3. Autism Spectrum Disorder
    • 7.3.1. Global Neurological Biomarkers Market, by Autism Spectrum Disorder, By Region, 2019-2032 (USD Billion)
  • 7.4. Parkinson's Disease
    • 7.4.1. Global Neurological Biomarkers Market, by Parkinson's Disease, By Region, 2019-2032 (USD Billion)
  • 7.5. Alzheimer's Disease
    • 7.5.1. Global Neurological Biomarkers Market, by Alzheimer's Disease, By Region, 2019-2032 (USD Billion)
  • 7.6. Multiple Sclerosis
    • 7.6.1. Global Neurological Biomarkers Market, by Multiple Sclerosis, By Region, 2019-2032 (USD Billion)
  • 7.7. Others
    • 7.7.1. Global Neurological Biomarkers Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Neurological Biomarkers Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Neurological Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Neurological Biomarkers Market - North America
    • 8.3.1. North America: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.3.3. North America: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.3.4. Neurological Biomarkers Market - U.S.
      • 8.3.4.1. U.S.: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.3.5. Neurological Biomarkers Market - Canada
      • 8.3.5.1. Canada: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 8.4. Neurological Biomarkers Market - Europe
    • 8.4.1. Europe: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.4. Neurological Biomarkers Market - UK
      • 8.4.4.1. UK: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.5. Neurological Biomarkers Market - France
      • 8.4.5.1. France: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.6. Neurological Biomarkers Market - Germany
      • 8.4.6.1. Germany: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.7. Neurological Biomarkers Market - Italy
      • 8.4.7.1. Italy: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.8. Neurological Biomarkers Market - Spain
      • 8.4.8.1. Spain: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.9. Neurological Biomarkers Market - Netherlands
      • 8.4.9.1. Netherlands: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.10. Neurological Biomarkers Market - Russia
      • 8.4.10.1. Russia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 8.5. Neurological Biomarkers Market - Asia Pacific
    • 8.5.1. Asia Pacific: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.4. Neurological Biomarkers Market - China
      • 8.5.4.1. China: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.5. Neurological Biomarkers Market - India
      • 8.5.5.1. India: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.6. Neurological Biomarkers Market - Malaysia
      • 8.5.6.1. Malaysia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.7. Neurological Biomarkers Market - Japan
      • 8.5.7.1. Japan: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.8. Neurological Biomarkers Market - Indonesia
      • 8.5.8.1. Indonesia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.9. Neurological Biomarkers Market - South Korea
      • 8.5.9.1. South Korea: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 8.6. Neurological Biomarkers Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.4. Neurological Biomarkers Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.5. Neurological Biomarkers Market - UAE
      • 8.6.5.1. UAE: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.6. Neurological Biomarkers Market - Israel
      • 8.6.6.1. Israel: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.7. Neurological Biomarkers Market - South Africa
      • 8.6.7.1. South Africa: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 8.7. Neurological Biomarkers Market - Latin America
    • 8.7.1. Latin America: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.4. Neurological Biomarkers Market - Mexico
      • 8.7.4.1. Mexico: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.5. Neurological Biomarkers Market - Brazil
      • 8.7.5.1. Brazil: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.6. Neurological Biomarkers Market - Argentina
      • 8.7.6.1. Argentina: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Alseres Pharmaceuticals, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. BANYAN BIOMARKERS, INC.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bio-Rad Laboratories, Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. DiaGenic ASA
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Johnson & Johnson Services, Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Merck & Co., Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Myriad Genetics, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Quanterix
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Thermo Fisher Scientific, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 3 Global Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 4 Neurological Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 7 North America: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 8 U.S.: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 10 U.S.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 11 Canada: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 13 Canada: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 14 Europe: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 16 Europe: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 17 UK: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 19 UK: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 20 France: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 22 France: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 23 Germany: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 25 Germany: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 26 Italy: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 28 Italy: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 29 Spain: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 31 Spain: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 35 Russia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 37 Russia: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 41 China: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 43 China: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 44 India: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 46 India: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 50 Japan: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 52 Japan: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 56 South Korea: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 58 South Korea: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 65 UAE: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 67 UAE: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 68 Israel: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 70 Israel: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 71 South Africa: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 73 South Africa: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 74 Latin America: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 76 Latin America: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 77 Mexico: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 79 Mexico: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 80 Brazil: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 82 Brazil: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 83 Argentina: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 85 Argentina: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Neurological Biomarkers Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by End Use
  • Figure 7. Global Neurological Biomarkers Market, by End Use, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Neurological Biomarkers Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Application
  • Figure 11. Global Neurological Biomarkers Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 12. Neurological Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Neurological Biomarkers Market